BOSTON, July 6, 2026
CervoMed Inc. announced that new clinical findings on its investigational therapy neflamapimod will be presented in five scientific presentations at the Alzheimer’s Association International Conference (AAIC) 2026, taking place in London, United Kingdom, from July 12–15. The presentations will highlight data demonstrating neflamapimod’s potential to slow disease progression in dementia with Lewy bodies (DLB), reduce neurodegeneration, preserve brain structure, optimize dosing strategies, and improve assessment of clinically meaningful treatment outcomes. The company’s research further strengthens the growing body of evidence supporting neflamapimod as a potential disease-modifying therapy for DLB, an area where no approved treatments currently exist in the United States or European Union.
Clinical Analyses Explore Disease Progression, Biomarkers, and Optimal Dosing
The AAIC presentations include multiple analyses from CervoMed’s Phase 2 clinical development program evaluating neflamapimod in patients with DLB. Researchers will present exploratory findings examining the therapy’s impact on clinical progression among patients with lower plasma p-tau181 levels and higher circulating drug concentrations, suggesting patient characteristics that may predict greater therapeutic benefit. Additional presentations will report MRI-based analyses demonstrating the drug’s potential to slow basal forebrain atrophy, an emerging biomarker closely associated with DLB progression. Pharmacokinetic and pharmacodynamic analyses will further evaluate exposure-response relationships and inhibition of interleukin-1β (IL-1β) signaling, helping define optimal dosing strategies for future clinical development. The conference will also feature initial clinical data from an open-label study evaluating 80 mg twice-daily dosing, including safety, tolerability, and pharmacokinetic findings.
Neflamapimod Targets Neuroinflammation and Synaptic Dysfunction
Neflamapimod is an investigational oral small-molecule therapy designed to selectively inhibit the p38 alpha MAP kinase, an enzyme involved in neuroinflammation and synaptic dysfunction that contributes to progressive neurodegenerative diseases. The therapy readily crosses the blood-brain barrier and is intended to restore neuronal function, improve synaptic health, and potentially slow disease progression. Across Phase 1 and Phase 2 clinical studies involving more than 800 participants, neflamapimod has demonstrated a favorable tolerability profile together with encouraging efficacy signals. Earlier studies, including the Phase 2a AscenD-LB trial and the larger Phase 2b RewinD-LB trial, reported improvements in cognition, functional mobility, dementia severity, and biomarkers of neurodegeneration, with the greatest benefits observed in patients without underlying Alzheimer’s disease pathology.
Advertisement
Clinical Development Continues Across Multiple Neurodegenerative Disorders
Beyond dementia with Lewy bodies, CervoMed continues to evaluate neflamapimod across a broader portfolio of neurodegenerative disorders. The investigational therapy is also being studied for recovery after ischemic stroke and primary progressive aphasia, while the company plans to initiate a Phase 2a study in amyotrophic lateral sclerosis (ALS) later this year. Following discussions with the U.S. Food and Drug Administration, CervoMed has established a potential regulatory pathway for advancing neflamapimod into Phase 3 development for DLB and is currently seeking a strategic partner to support late-stage clinical development. The extensive AAIC 2026 presentation program reflects the company’s continued commitment to developing disease-modifying therapies for neurodegenerative disorders where substantial unmet medical need remains.
Source: CervoMed press release
